These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31237921)

  • 1. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.
    Grenet G; Ribault S; Nguyen GB; Glais F; Metge A; Linet T; Kassai-Koupai B; Cornu C; Bejan-Angoulvant T; Erpeldinger S; Boussageon R; Gouraud A; Bonnet F; Cucherat M; Moulin P; Gueyffier F
    PLoS One; 2019; 14(6):e0217701. PubMed ID: 31237921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y; Tsoi MF; Cheung BMY
    Cardiovasc Diabetol; 2019 Aug; 18(1):112. PubMed ID: 31462224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of the Combination or Monotherapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: An update Systematic Review and Meta-analysis.
    Tuersun A; Hou G; Cheng G
    Am J Med Sci; 2024 Jul; ():. PubMed ID: 38977245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis.
    Bilal A; Yi F; Gonzalez GR; Ali M; Im K; Ruff CT; Thethi TK; Pratley RE
    J Diabetes Complications; 2024 Jun; 38(8):108783. PubMed ID: 38870731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis.
    Kim JS; Lee G; Park KI; Oh SW
    Diabetes Metab J; 2024 Mar; 48(2):312-320. PubMed ID: 38273787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.
    Gu Y; Sun L; Zhang W; Kong T; Zhou R; He Y; Deng C; Yang L; Kong J; Chen Y; Shi J; Hu Y
    Front Pharmacol; 2023; 14():1102792. PubMed ID: 36992825
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review.
    Georgiou P; Shi W; Serhiyenia T; Akram A; Proute MC; Pradeep R; Kerolos ME; Khan S
    Cureus; 2021 Oct; 13(10):e18485. PubMed ID: 34754647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review.
    Ntentakis DP; Correa VSMC; Ntentaki AM; Delavogia E; Narimatsu T; Efstathiou NE; Vavvas DG
    Graefes Arch Clin Exp Ophthalmol; 2024 Mar; 262(3):717-752. PubMed ID: 37728754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study.
    Wai KM; Mishra K; Koo E; Ludwig CA; Parikh R; Mruthyunjaya P; Rahimy E
    Am J Ophthalmol; 2024 Apr; 265():39-47. PubMed ID: 38636788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of first-line antidiabetic drugs on the improvement of arterial stiffness: A Bayesian network meta-analysis.
    Wang J; Wang Y; Wang Y; Li Y; Zhang J; Zhang H; Fu X; Guo Z; Yang Y; Kang K; Zhang W; Tian L; Wu Y; Xin S; Liu H
    J Diabetes; 2023 Aug; 15(8):685-698. PubMed ID: 37165762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis.
    Mattay SS; Zamani M; Saturno D; Loftus EV; Ciorba MA; Yarur A; Singh S; Deepak P
    Clin Gastroenterol Hepatol; 2024 May; 22(5):961-970.e12. PubMed ID: 37821035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS.
    Blonde L; Fonseca V
    Endocr Pract; 2018 Aug; ():. PubMed ID: 30084684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.
    Sorice GP; Cinti F; Leccisotti L; D'Amario D; Lorusso M; Guzzardi MA; Mezza T; Cocchi C; Capece U; Ferraro PM; Crea F; Giordano A; Iozzo P; Giaccari A
    Diabetes Ther; 2021 Jul; 12(7):2101-2113. PubMed ID: 34037951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefits of GLP1 receptors in cardiovascular diseases.
    Ferhatbegović L; Mršić D; Macić-Džanković A
    Front Clin Diabetes Healthc; 2023; 4():1293926. PubMed ID: 38143794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Liang T; Xie X; Wu L; Li L; Yang L; Gao H; Deng Z; Zhang X; Chen X; Zhang J; Ding Y; Wu Q
    Front Nutr; 2022; 9():825897. PubMed ID: 35923194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
    Schnell O; Valensi P; Standl E; Ceriello A
    Endocrinol Diabetes Metab; 2020 Jul; 3(3):e00129. PubMed ID: 32704554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists.
    Khedagi A; Hoke C; Kelsey M; Coviello A; Jones WS; Jackson LR; Patel MR; McGarrah RW; Pagidipati NJ; Shah NP
    Am J Prev Cardiol; 2023 Mar; 13():100477. PubMed ID: 36915710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists.
    Piccini S; Favacchio G; Morenghi E; Mazziotti G; A Lania AG; Mirani M
    Diabetes Res Clin Pract; 2024 Jun; 212():111689. PubMed ID: 38697297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis.
    Alatawi AM
    Pak J Med Sci; 2024; 40(1Part-I):209-213. PubMed ID: 38196460
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.